Published: 2016-12-15

Radiation versus paclitaxel chemo radiation in the treatment of locally advanced carcinoma of cervix

Elamurugan Sujindra, Latla Chaturvedula


Background: Cervical cancer is the most common malignancy among women. Incomplete local control and the appearance of distant disease herald poor survival. Concurrent chemo radiation is recently developing as the preferred modality of treatment. The objective of this study was to compare the effectiveness of concurrent Paclitaxel chemo radiation to that of only radiation in treatment of patients with locally advanced squamous cell cervical cancer.

Methods: The study was carried out at JIPMER, Puducherry from October 2005 to October 2010. There were two groups with 25 patients each. Group 1 received only radiation - 4860 cGy EBRT daily in five fractions per week for a total of 27 fractions followed by HDR brachytherapy. Group 2 received 50 mg/m2 of Paclitaxel on all Mondays followed by concurrent radiotherapy. Patients were assessed at 6 months and 1 year after completion of treatment. In October 2010 they were all examined to calculate four year survival and disease free survival rate.

Results: A total of 48 patients were analyzed. Complete response rate was 56% in group 1 and 72% in group 2. At the end of four years survival and disease free survival rate in group 1 was 57.9% and 31.6% and in group 2 was 57.1% and 33.3% respectively.

Conclusions: Concurrent chemo radiation with Paclitaxel gives promising results and is more effective method than treatment with only radiation.


Radiation, Chemo radiation, Paclitaxel, Locally advanced, Carcinoma cervix

Full Text:



Mohar A, Frias-Mendivil M. Epidemiology of cervical cancer. Cancer Invest. 2000;18:584-90.

Gonzalez AD, Cetina L, Mariscal I, Garza J. Modern management of locally advanced cervical carcinoma. Cancer Treat Rev. 2003;29:389-99.

Singh TT, Singh IY, Sharma DT, Singh NRK. Role of chemo radiation in advanced cervical cancer. Indian J Canc. 2003;40:101-7.

Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-53.

Jampolis S, Andras EJ, Fletcher GH. Analysis of sites and causes of failure of irradiation in invasive squamous cell carcinoma of the intact uterine cervix. Radiology. 1975;115:681-95.

Perez CA, Camel HM, Kuske RR, Kao MS, Galakatos A, Hederman MA, et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix: a 20 years’ experience. Gynecol Oncol. 1986;23:127-40.

Rotman MZ. Chemo irradiation: a new initiative in cancer treatment: 1991 RSNA annual oration in radiation oncology. Radiology. 1992;184:319-27.

Thomas G, Dembo A, Fyles A, Gadalla T, Beale F, Bean H, et al. Concurrent chemoradiation in advanced cervical cancer. Gynecol Oncol. 1980;38:446-51.

Terauchi F, Nagashima T, Kobayashi Y, Yamamoto Y, Moritake T, Seiki T, et al. A pilot study for weekly paclitaxel administration for patients with relapsed cervical cancer after heavy medication. Gan To Kagaku Ryoho. 2005;32:641-4.

Tinker AV, Bhagat K, Swenerton KD, Hoskins PJ. Carboplatin and Paclitaxel for advanced and recurrent cervical cancinoma: the British Columbia Cancer Agency experience. Gynecol Oncol. 2005;98:54-8.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL. Phase I clinical trial of weekly paclitaxel, weekly carboplatin and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol. 2005;96:168-72.

Lee MY, Wu HG, Kim K, Ha SW, Kim KS, Kim IA, et al. Concurrent radiotherapy with Paclitaxel/Carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of uterine cervix. Gynecol Oncol. 2007;104:95-9.